An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …

The development of vaccines against SARS-CoV-2 would be greatly facilitated by the
identification of immunological correlates of protection in humans. However, to date, studies on …

Antibodies are a potential therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
but the risk of the virus evolving to escape them remains unclear. Here we map …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …

The recent emergence of SARS-CoV-2 variants of concern 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10
and the recurrent spillovers of coronaviruses 11 , 12 into the human population highlight the …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern comprises several sublineages, with BA.2 and BA.2.12.1 having replaced the …

Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots
in the receptor-binding domain 1 (RBD) of the spike protein. The effects of these mutations …

New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue
to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a …

RNA viruses that replicate in the cytoplasm often disrupt nucleocytoplasmic transport to
preferentially translate their own transcripts and prevent host antiviral responses. The …

Immune imprinting describes how the first exposure to a virus shapes immunological
outcomes of subsequent exposures to antigenically related strains. Severe acute respiratory …